<DOC>
	<DOCNO>NCT02660619</DOCNO>
	<brief_summary>The purpose validate PRISM-5-Op measurement prescription opioid substance use disorder .</brief_summary>
	<brief_title>Validation PRISM-5-Op , Measure Of Addiction To Prescription Opioid Medication</brief_title>
	<detailed_description>`` Based review literature , Food Drug Administration ( FDA ) conclude data need regard serious risk misuse , abuse , addiction , overdose , death associate long-term use extend release/long acting ( ER/LA ) opioid analgesic . Thus , FDA require ER/LA opioid analgesic drug sponsor conduct post-marketing study assess risk . The present study , PMR Study # 2065-2 , focus addiction , address FDA requirement conduct validation study measure addiction use PMR Study # 2065-1 . The primary objective Study 2b validate PRISM-5-Op measure DSM-5 prescription opioid SUD/addiction patient , , prescription opioids least 30 day treat chronic pain ''</detailed_description>
	<mesh_term>Behavior , Addictive</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>1 . Has prescription opioids chronic pain least 30 day 2 . Age 18 year old Englishspeaking 3 . Willing able provide inform consent '' 1 . Patient hear vision impairment would preclude interview completion selfadministered questionnaire 2 . Patient cognitively impair give informed consent participate evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>